Inhaled insulin is a rapid-acting form of insulin delivered as a dry powder through the mouth and into the lungs, where it passes into the bloodstream faster than any injected rapid-acting insulin on the market. The only currently available product is Afrezza (Technosphere insulin), approved in the United States for adults with type 1 or type 2 diabetes. The idea of breathing in insulin instead of injecting it has been around for decades, but the path to a viable product was rocky, and the version you can get today works quite differently from the one that failed spectacularly in 2007.
How It Reaches the Bloodstream
Afrezza uses a carrier molecule called fumaryl diketopiperazine, or FDKP, which forms tiny microparticles that adsorb insulin onto their surface.1PubMed. Technosphere inhaled insulin (Afrezza) When you inhale the powder through a small, thumb-sized device, these particles travel deep into the lungs, reaching the alveoli, the thin-walled air sacs where gas exchange happens.2PubMed. AFREZZA® (insulin human) Inhalation Powder: A Review in Diabetes Mellitus The alveoli have an enormous surface area and extremely thin membranes, which is why insulin can cross into the bloodstream rapidly from there. Once in circulation, it works exactly like any other human insulin, binding to the same receptors and lowering blood sugar the same way. The FDKP carrier itself is inert and gets excreted by the kidneys.
Faster Than a Needle
The speed advantage is the central selling point. In a head-to-head comparison, inhaled insulin reached its early half-maximal effect in about 32 minutes, compared with 41 minutes for insulin lispro (a fast-acting injected analog) and 48 minutes for regular human insulin.3Diabetes Care. Time-Action Profile of Inhaled Insulin in Comparison With Subcutaneously Injected Insulin Lispro and Regular Human Insulin The peak serum insulin level after inhalation can arrive in as little as 5 to 60 minutes, while subcutaneous injection typically peaks between 60 and 150 minutes.4Advanced Drug Delivery Reviews. Inhaled insulin That faster onset and faster clearance make the drug’s action curve look more like the natural burst of insulin your pancreas releases after a meal.
The flip side of speed is duration. Inhaled insulin’s glucose-lowering effect fades more quickly than injected analogs. In practice, that means it handles the initial post-meal blood sugar spike very well but may leave you less covered a couple of hours later, especially after high-fat or high-carb meals that digest slowly.5International Journal of Scientific Research and Technology. Afrezza (Technosphere® Inhaled Insulin) In The Management Of Postprandial Hyperglycemia
Blood Sugar Control in Clinical Trials
In people with type 2 diabetes who were not getting adequate control from oral medications alone, adding inhaled insulin dropped HbA1c by roughly 2.3 percentage points over 12 weeks, while the group that stayed on oral medications alone saw almost no change.6Annals of Internal Medicine. Inhaled Insulin Provides Improved Glycemic Control in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Agents That is a large effect, reflecting a population whose blood sugar was quite poorly controlled at the start. In a year-long study comparing Afrezza plus basal insulin against a standard premixed insulin regimen in type 2 diabetes, HbA1c reductions were similar between the two groups, with the inhaled insulin arm showing less weight gain and fewer hypoglycemic episodes.7The Lancet. Efficacy and safety of Technosphere inhaled insulin compared with twice daily biaspart insulin in patients with type 2 diabetes
For type 1 diabetes, a recent 13-week study evaluated adults who switched from either multiple daily injections or an automated insulin delivery system to Afrezza paired with once-daily insulin degludec. Daytime time-in-range rose by about 5 percentage points, and the proportion of participants meeting an HbA1c target below 7% doubled from 14% to 31%.8PubMed. A 13-Week Single-Arm Evaluation of Inhaled Technosphere Insulin Plus Insulin Degludec for Adults with Type 1 Diabetes The improvements were modest but statistically meaningful, and they came with a familiar trade-off worth understanding: the fast-in, fast-out action curve.
Taming Post-Meal Spikes
Where inhaled insulin clearly shines is in blunting the early surge in blood sugar after eating. A randomized comparison in adults with type 1 diabetes found that Afrezza produced a smaller glucose excursion, a lower peak glucose, and a shorter time to peak compared with injected rapid-acting analog insulin.9PubMed Central. A Randomized Comparison of Postprandial Glucose Excursion Using Inhaled Insulin Versus Rapid-Acting Analog Insulin in Adults With Type 1 Diabetes Even when layered on top of a hybrid closed-loop insulin pump, adding an Afrezza bolus before meals significantly reduced the early post-meal glucose level at 30 minutes, though the benefit faded by two to three hours.10PubMed Central. Effect of Afrezza on Glucose Dynamics During HCL Treatment
Simulation work has suggested that dosing Afrezza after a meal, or splitting the dose between pre-meal and post-meal, could extend its glucose-lowering coverage and reduce hypoglycemia risk compared with a single pre-meal injection of a rapid-acting analog.11PubMed Central. Improving Efficacy of Inhaled Technosphere Insulin (Afrezza) by Postmeal Dosing Some users in practice already dose this way, treating the fast peak as a tool for the first wave of glucose and then following up if a slow-digesting meal keeps blood sugar elevated.
Less Hypoglycemia and Less Weight Gain
A systematic review and meta-analysis pooling data from type 1 diabetes trials found that inhaled insulin was associated with less weight gain and fewer hypoglycemic events than injected comparators, with a similar overall effect on blood sugar levels.12PubMed Central. Comparative Analysis of Inhaled Insulin With Other Types in Type 1 Diabetes Mellitus A post-hoc analysis from a type 1 diabetes trial found that total and severe hypoglycemia rates were about 26% lower with Afrezza than with insulin aspart across the full HbA1c range.13Diabetes. Total and Severe Hypoglycemia Is Reduced with Use of Inhaled Technosphere Insulin (TI, Afrezza®) Relative to Insulin Aspart in Type 1 Diabetes Even the earlier Exubera trials, using a different formulation, showed slightly lower overall hypoglycemia in the inhaled group than in the subcutaneous group.14Diabetes Care. Efficacy and Safety of Inhaled Insulin (Exubera) Compared With Subcutaneous Insulin Therapy in Patients With Type 2 Diabetes
The likely explanation is straightforward. Because inhaled insulin hits fast and clears fast, it does not linger in the bloodstream the way longer-acting injected bolus insulin can. That lingering is what causes late hypoglycemia, the kind that catches people two or three hours after a meal. Less circulating insulin later means less risk of blood sugar dropping too low, and less persistent insulin signaling also means less of the appetite-stimulating and fat-storage effects that make mealtime insulin a driver of weight gain.
The Cough and What It Means for Your Lungs
The most common side effect of Afrezza is cough, and it is not subtle. A meta-analysis of seven trials found that mild, transient cough was about eight times more likely in people using inhaled insulin than in those using injected comparators.15The Lancet Diabetes & Endocrinology. Efficacy, safety, and patient acceptability of Technosphere inhaled insulin in patients with diabetes For most users the cough is brief and fades within a few weeks of regular use, but it remains the reason some people stop the medication early.
Beyond cough, there is a small but measurable decline in a lung function metric called FEV1, basically how much air you can blow out in one second. The same meta-analysis estimated a net decrease of about 0.038 liters with inhaled insulin compared with injected treatment.16The Lancet Diabetes & Endocrinology. Efficacy, safety, and patient acceptability of Technosphere inhaled insulin in patients with diabetes A two-year study of the earlier Exubera product found that the FEV1 difference appeared within the first three months of use and did not keep getting worse after that, suggesting the lungs adapt rather than progressively deteriorate.17Diabetes Care. Two-Year Safety and Efficacy of Inhaled Human Insulin (Exubera) in Adult Patients With Type 1 Diabetes Prescribing guidelines call for lung function testing before starting treatment and periodically thereafter.
The more alarming question, lung cancer, arose from Exubera’s clinical trial data. A follow-up study of former Exubera trial participants could not rule out a very small increase in lung-cancer-related death, estimated at roughly 0.48 extra cases per 1,000 person-years. All-cause mortality, however, was not elevated in former Exubera users.18Diabetes Care. Lung Cancer–Related Mortality With Inhaled Insulin or a Comparator For Afrezza specifically, long-term animal studies in rats and dogs found no carcinogenic potential, and microscopic changes in respiratory tissue were attributed to the carrier particle itself rather than the insulin, limited to nasal tissue rather than the deep lung.19PubMed. Long-Term Nonclinical Pulmonary Safety Assessment of Afrezza, a Novel Insulin Inhalation Powder The evidence so far does not suggest Afrezza carries a meaningful lung cancer risk, but the Exubera signal is a legitimate reason regulators remain watchful.
Who Should Not Use It
Afrezza is contraindicated in people with asthma or chronic obstructive pulmonary disease. In these patients, inhaling the powder can trigger acute bronchospasm, a sudden tightening of the airways that is dangerous and unpredictable.20Current Drug Safety. Safety of Technosphere Inhaled Insulin This is a hard contraindication, not a relative one. If you have either condition, inhaled insulin is off the table regardless of how well-controlled your lung disease is. Active smokers face a different but related concern discussed below.
Smoking Changes Everything About Absorption
Smoking dramatically alters how much inhaled insulin gets into your bloodstream and how fast it gets there. In one study, smokers reached a peak insulin concentration almost three times higher than nonsmokers and hit that peak in about 20 minutes instead of 53.21PubMed. The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin After quitting, the area under the insulin curve dropped by up to 50% within a week and approached nonsmoker levels, but peak concentration and time to peak had not fully normalized. Resuming smoking even briefly reversed the changes completely.
The mechanism is that smoking increases the permeability of the lung’s epithelial lining, letting more insulin cross into the blood. Chronic smoking, acute smoking, and even passive smoke exposure all affect absorption differently, making dose titration unreliable in anyone with fluctuating exposure.22PubMed Central. A Review of the Impact of Smoking on Inhaled Insulin This is why current labeling recommends against use in active smokers and why anyone who quits or restarts smoking while on inhaled insulin needs close monitoring and dose adjustments.
Dosing in Practice
Afrezza comes in single-use cartridges of 4, 8, and 12 units. You can combine cartridges for larger doses, but you cannot dose in anything smaller than 4-unit increments. For someone used to dialing an insulin pen to the exact unit, that feels coarse. The standard conversion when switching from injected rapid-acting insulin is to double the subcutaneous dose and round down to the nearest available cartridge size.23ScienceDirect / AACE Endocrinology and Diabetes. Inhaled Insulin Dosing in a Randomized Trial in Adults With Type 1 Diabetes The reason for the higher number is that not all inhaled insulin reaches the deep lung; some is deposited in the mouth, throat, and upper airways. So the delivered dose to the bloodstream is lower per unit than what the cartridge label says.
In a clinical trial tracking dosing over 30 weeks, the average total daily Afrezza dose rose from 36 units at baseline to 52 units by the end, and about three-quarters of participants had increased their dose by more than 4 units by that point.24ScienceDirect / AACE Endocrinology and Diabetes. Inhaled Insulin Dosing in a Randomized Trial in Adults With Type 1 Diabetes Titration takes time and experimentation, and the 4-unit steps mean some meals end up slightly over- or under-dosed relative to what a pen or pump could deliver. For people eating very consistent meals this matters less; for those with highly variable carbohydrate intake, the imprecision can be frustrating.
Why Exubera Failed and Why That Still Matters
Afrezza is not the first inhaled insulin. Pfizer’s Exubera reached the market in 2006 and was pulled within a year, a commercial disaster that scared the entire industry away from the pulmonary insulin concept for years.25PubMed Central. The failure of exubera: are we beating a dead horse? The problems were multiple: the inhaler device was large and conspicuous, about the size of a tennis-ball can. Dosing was complicated. Pricing was aggressive. And physicians, already cautious about a new delivery route, had little incentive to prescribe something that was not clearly superior to a well-understood injection. The lung cancer signal that emerged later added to the product’s troubled legacy.
Afrezza’s designers learned from most of those mistakes. The inhaler is small enough to fit in a pocket, the cartridge system is simpler, and the Technosphere carrier provides a more consistent pharmacokinetic profile than Exubera’s dry-powder formulation. But the Exubera hangover still shapes the market. Insurers treat inhaled insulin as a specialty product, many endocrinologists have limited experience prescribing it, and the lung cancer question, even though the data point toward Afrezza being safe, remains a talking point that slows adoption.
Patient Experience and the Cost Problem
For people who dread needles, inhaled insulin removes the most visible barrier to mealtime insulin use. Patients with higher levels of injection fear and expected hardship from insulin therapy were more likely to prefer inhaled delivery in a study of treatment preferences.26PubMed. Psychological insulin resistance in type 2 diabetes patients regarding oral antidiabetes treatment, subcutaneous insulin injections, or inhaled insulin That said, the same study found that the option of inhalation increased acceptability for some but not most patients, suggesting that needle aversion is a genuine but not universal driver of insulin avoidance. Broader reviews confirm that people using Afrezza generally report higher treatment satisfaction compared with injected rapid-acting insulin, alongside comparable HbA1c reductions and fewer lows.27PubMed. The Potential of Inhaled Insulin Therapy in Overcoming Treatment Barriers in People with Insulin-Treated Diabetes
The biggest practical obstacle is cost. In a real-world registry of adults with type 1 diabetes, current users rated perceived effectiveness as the most important reason to keep using inhaled insulin, while past users who had discontinued rated out-of-pocket cost as the most important reason they stopped.28PubMed. Experiences With Inhaled Insulin in a Real-World Sample of Adults With Type 1 Diabetes in the T1D Exchange Registry Afrezza is typically more expensive than injected rapid-acting analogs, and insurance coverage varies widely. For many people, the convenience and speed advantages are real but not compelling enough to justify a substantially higher copay, especially when injected options control blood sugar adequately.
Inhaled Insulin in Children
Afrezza is currently approved only for adults, but a multicenter randomized trial called INHALE-1 recently tested it in children with type 1 diabetes. Over 26 weeks, the study did not formally meet its prespecified bar for HbA1c noninferiority against injected rapid-acting analog insulin. HbA1c rose slightly in the inhaled insulin group (from about 8.2% to 8.4%) while staying flat in the injected group. Time in range on continuous glucose monitoring was not significantly different between the two arms.29PubMed Central. INHALE-1: A Multicenter Randomized Trial of Inhaled Technosphere Insulin in Children With Type 1 Diabetes
On the positive side, lung function did not differ between groups, severe hypoglycemia was rare in both arms, and children using inhaled insulin reported significantly greater treatment satisfaction and gained less weight.30PubMed Central. INHALE-1: A Multicenter Randomized Trial of Inhaled Technosphere Insulin in Children With Type 1 Diabetes An extension study followed children on inhaled insulin out to 52 weeks and found that HbA1c drifted upward modestly, with no serious or unexpected pulmonary adverse events. Lung function measured after stopping Afrezza was unchanged from baseline.31PubMed. Inhaled Technosphere Insulin in Children with Diabetes: The INHALE-1 Extension Study The study authors framed the results as supporting inhaled insulin as a potential option for some pediatric patients, though the HbA1c gap means regulatory approval for children is not imminent.
For families, the treatment satisfaction finding may matter as much as the HbA1c data. Managing type 1 diabetes in a child involves multiple daily injections, and anything that reduces the daily burden of needles, even for some of those doses, can meaningfully affect quality of life. Whether that trade-off is worth a slightly less tight HbA1c is the kind of decision that depends on the individual child, their current control, and how much injection-related distress they experience.
The Particle Engineering Behind the Cartridge
Getting insulin to the deep lung requires remarkably precise particle engineering. Particles that are too large get caught in the throat or upper airways and never reach the alveoli. Particles that are too small may be exhaled right back out before depositing. The sweet spot is roughly 1 to 5 micrometers in aerodynamic diameter. Research into pure insulin powders without excipients has achieved particles with a median aerodynamic diameter under 2 micrometers and a fine particle fraction above 80%, meaning the vast majority of the dose reaches the respirable range.32PubMed Central. Pure insulin highly respirable powders for inhalation Afrezza’s Technosphere particles are engineered within this window, and the consistency of the particle size distribution is what allows the product to deliver a reasonably predictable dose breath to breath.
This engineering challenge is part of why inhaled insulin took decades to get right and why generic competition has been slow to materialize. Reproducing the inhaler-plus-particle system to the same pharmacokinetic standard is harder than copying a molecule in solution. The intellectual property around Technosphere technology, combined with the regulatory burden of proving bioequivalence for an inhalation product, means Afrezza has the niche largely to itself for now.